PubMed · 1996 · 41 citations · 22 references
MedicineGeneticsOncologyCarcinogenesisMolecular OncologyNeoplasiaBiliary Tract CancerCancer EtiologyCancer Molecular PathologyHepatobiliary CancerHepatobiliary PathologyMalignant NeoplasmsGallbladder CarcinomaImmunohistochemical StainingMissense MutationsMutation Spectrum AnalysisOncogenic Mutation SpectrumP53 MutationTp53 MutationsTransversion Mutations
p53 mutations in adenocarcinomas of the gallbladder were analyzed by deoxynucleotide sequencing of the gene. Of 23 cases, 16 (70%) harbored 18 missense mutations in exon 5, 6, or 8 of the p53 gene. The characteristics of the p53 mutation spectrum observed in gallbladder carcinomas were (a) frequent mutations at an A:T pair [10 (55%) of 18 mutations], (b) high transversion incidence [12 (66%) of 18 mutations], and (c) only one mutation at the CpG site. The immunohistochemical study revealed that 36 (55%) of 65 cases showed an abnormal accumulation of p53 immunoreactivity, and 12 (52%) of 23 cases had p21 expression. No statistical correlation was observed between p53 and p21 immunoreactivity. These results suggest that p53 mutations may confer the carcinogenesis of the adenocarcinoma of the gallbladder with the specific mutation spectrum of p53.
22
WAF1, a potential mediator of p53 tumor suppression
Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell · 1993 · 8.4K citations
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Marc S. Greenblatt, W P Bennett, Monica Hollstein et al. · PubMed · 1994 · 3.5K citations
p21 is a universal inhibitor of cyclin kinases
Yue Xiong, Gregory J. Hannon, Hui Zhang et al. · Nature · 1993 · 3.4K citations
Mutations in the p53 gene occur in diverse human tumour types
Janice Nigro, Suzanne J. Baker, Antonette C. Preisinger et al. · Nature · 1989 · 2.8K citations · Full text